US FDA asks for more info on J&J's Doribax
This article was originally published in Scrip
The US FDAhas told Johnson & Johnsonthat it will require additional information before approving the intravenous antibiotic Doribax (doripenem) for the additional use of treating hospital-acquired pneumonia, including ventilator-associated pneumonia (VAP).
You may also be interested in...
Amgen's investigational bone loss treatment denosumab more than halves osteoporosis patients' risk of new vertebral fractures, new data from a pivotal Phase III trial show.
Gilead Scienceswill need to conduct another clinical trial of its investigational cystic fibrosis treatment aztreonam lysine for inhalation before the drug can be approved, the US FDAhas said.